GlassScriptPhysician profile
Kimberly Ann Cooper
NPI 1386050524
$1,192.16
in general payments reported to CMS, 2019-2025
33 companies · $291 in 2025
The $291 reported for 2025 was more than what 84% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $43.41 · 2020: $40.93 · 2022: $102 · 2023: $224 · 2024: $491 · 2025: $291.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,006.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,005.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $98.84 | 2022-2024 | Vaxelis, Gardasil 9, M-M-R II |
| Sanofi-Aventis U.S. LLC | $86.47 | 2024-2025 | |
| Glaxosmithkline, LLC. | $77.09 | 2022-2024 | Shingrix, Arexvy |
| Ironshore Pharmaceuticals INC. | $75.48 | 2019-2024 | Jornay Pm |
| Otsuka America Pharmaceutical, INC. | $69.37 | 2024-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Abiomed | $66.16 | 2024-2025 | Impella |
| Axsome Therapeutics, INC. | $50.22 | 2024-2025 | Auvelity |
| Antares Pharma, INC. | $46.60 | 2023-2024 | Xyosted, Nocdurna, Tlando |
| Amgen INC. | $44.68 | 2022-2023 | Prolia, Evenity, Otezla |
| Collegium Pharmaceutical, INC. | $43.67 | 2025 | Jornay Pm |
| Xeris Pharmaceuticals, INC. | $43.64 | 2023-2024 | Gvoke Hypopen |
| Exact Sciences Corporation | $41.95 | 2024-2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $39.00 | 2024-2025 | Farxiga |
| Corium, LLC | $38.24 | 2025 | Azstarys |
| Esperion Therapeutics, INC. | $37.61 | 2024-2025 | Nexletol |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $32.62 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.34 | 2020 | |
| Biomarin Pharmaceutical INC. | $26.74 | 2024 | Voxzogo 1.2mg |
| Seqirus USA INC | $23.45 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.99 | 2024 | Xifaxan |
| Cranial Technologies, INC | $18.89 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.32 | 2023 | |
| Abbvie INC. | $18.16 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.05 | 2024 | |
| Lilly USA, LLC | $16.59 | 2024 | Jardiance |
| Tandem Diabetes Care, INC. | $15.89 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Ironwood Pharmaceuticals, INC | $15.00 | 2024 | |
| Novo Nordisk INC | $14.67 | 2024 | Ozempic, Rybelsus |
| Ibsa Pharma INC. | $14.60 | 2023 | Tirosint, Licart |
| Novartis Pharmaceuticals Corporation | $13.80 | 2023 | |
| Sobi, INC | $13.59 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $13.38 | 2024 | Crysvita |
| Shire North American Group INC | $12.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Cooper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.